Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 249


Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM.

J Immunol. 2003 Apr 15;170(8):4273-80.


The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.

Cancer Res. 2001 Feb 1;61(3):880-3.


HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM.

Cancer Res. 2000 Jul 1;60(13):3569-76.


Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.

Geluk A, van Meijgaarden KE, Franken KL, Drijfhout JW, D'Souza S, Necker A, Huygen K, Ottenhoff TH.

J Immunol. 2000 Dec 1;165(11):6463-71.


Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.

Vertuani S, Sette A, Sidney J, Southwood S, Fikes J, Keogh E, Lindencrona JA, Ishioka G, Levitskaya J, Kiessling R.

J Immunol. 2004 Mar 15;172(6):3501-8.


HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.

Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR.

J Immunol. 2003 Oct 15;171(8):4054-61.


HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R.

Cancer Immunol Immunother. 2009 May;58(5):653-64. doi: 10.1007/s00262-008-0587-1. Epub 2008 Sep 27.


Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.

Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN.

Cancer Res. 2006 May 15;66(10):5452-60.


Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.

Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.

Cancer Res. 2004 Nov 1;64(21):8022-8.


Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.

Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2007 May;56(5):601-13. Epub 2006 Sep 8.


HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.

Chan T, Sami A, El-Gayed A, Guo X, Xiang J.

Gene Ther. 2006 Oct;13(19):1391-402. Epub 2006 May 25.


Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.

Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, Morris JC, Oshima RG, Kaumaya PT.

J Immunol. 2007 Jul 1;179(1):472-82.


DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.

Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ.

Cancer Res. 1998 May 1;58(9):1965-71.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk